Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier

Therapeutic Delivery

Volumn 1, Issue 4, 2010, Pages 571-586

  Gabathuler, Reinhard ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; APOLIPOPROTEIN B; APOLIPOPROTEIN E; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; INSULIN; INSULIN RECEPTOR; LACTOFERRIN; LIPOSOME; LOPERAMIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MONOCLONAL ANTIBODY; NANOPARTICLE; NERVE GROWTH FACTOR; NEUROTENSIN; POLYARGININE; PROPOFOL; PROTEIN P97; RIBAVIRIN; TRANSACTIVATOR PROTEIN; TRANSFERRIN; TRANSFERRIN RECEPTOR;

AMINO ACID SEQUENCE; AMNESIA; BLOOD BRAIN BARRIER; BRAIN TUMOR; DRUG BINDING; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PENETRATION; DRUG TRANSPORT; ENCEPHALITIS; ENDOCYTOSIS; GLIOBLASTOMA; HUMAN; LIGAND BINDING; LIPOPHILICITY; MEMBRANE TRANSPORT; NANOPHARMACEUTICS; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SEQUENCE ANALYSIS; TRANSCYTOSIS;

EID: 79952655204     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.35     Document Type: Review

References (116)

1. Brownlees J, Williams CH. Peptidases, peptides and the mammalian blood-brain barrier. J. Neurochem. 60, 1089-1096 (1993).
2. Alzheimer Society of Canada. Rising Tide: The Impact of Dementia on Canadian Society. ISBN 978-970-9733522-2-1 (2010).
3. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70, 1781-1792 (1998). (Pubitemid 28207799)
4. Pardridge WM. Drug targeting to the brain. Pharma. Res. 24, 1733-1744 (2007). (Pubitemid 47206623)
5. De Boer AG, Gaillard PJ. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 47, 323-355 (2007).
6. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J. Pharm. Pharmaceut. Sci. 6, 252-273 (2003) (Pubitemid 37207232)
7. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48-57 (2010).
8. Suhr ST, Gage FH. Gene therapy in the central nervous system. Arch. Neurol. 56, 287-292 (1999).
9. Sawada GA, Williams LR, Lutzke BS, Raub TJ. Novel, highly lipophilic antioxidants readily diffuse across the blood-brain barrier and access intracellular sites. J. Pharmacol. Exp. Ther. 288 (3), 1327-1333 (1999). (Pubitemid 29254174)
10. Raub TJ, Barsuhn CL, Williams LR, Decker DE, Sawada GA, Ho NF. Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J. Drug. Target. 1, 269-286 (1993).
11. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 22, 2329-2343 (2001).
12. Bredeloux P, Cavelier F, Dubuc I, Vivet B, Costentin J, Martinez J. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu- Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analog of neurotensin that crosses the blood- brain barrier. J. Med. Chem. 51, 1610-1616 (2008). (Pubitemid 351438845)
13. Chen W, Yang JZ, Andersen R, Nielsen LH, Borchardt RT. Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-d-Ala-Gly-Phe-d-Leu- OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model. J. Pharmacol. Exp. Ther. 303, 849-857 (2002).
14. Egleton RD, Mitchell SA, Huber JD et al. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res. 881, 37-46 (2000).
15. Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Controlled Rel. 130, 98-106 (2008).
16. Kabanov AV, Batrakova EV, Miller DW. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood- brain barrier. Adv. Drug Deliv. Rev. 55, 151-164 (2003). (Pubitemid 36078456)
17. Qu X, Khutoryanskiy VV, Stewart A et al. Carbohydrate-based micelle clusters which enhance hydrophobic drug availability by up to one order of magnitude. Biomacromolecules 7, 3452-3459 (2006). (Pubitemid 46111801)
18. Palmer AM. The blood-brain barrier. Neurobiol. Dis. 37, 1-2 (2010).
19. Gabathuler R. Blood-brain barrier transport of drugs for the treatment of brain diseases. CNS Neurol Disord. Drug Targets 8, 195-294 (2009).
20. Allen DD, Lockman PR, Roder KE, Dwoskin LP, Crooks PA. Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J. Pharmacol. Exp. Ther. 304, 1268-1274 (2003). (Pubitemid 36254440)
21. Gaillard PJ, Leyssen P, Appeldoorn C et al. Development of brain-targeted liposomes with antiviral drugs for treating lethal viral encephalitis. Presented at: The 8th Cerebral Vascular Biology (CVB) 2009 International Conference. Sendai, Japan, 28 June-2 July 2009.
22. Kannan R, Yi JR, Tang D, Zlokovic BV, Kaplowitz N. Evidence for the existence of a sodium-dependent glutathione (GSH) transporter. J. Biol. Chem. 271 (16), 9754-9758 (1996).
23. Kannan R, Yi J-R, Zlokovic BV, Kaplowitz N. Carrier-mediated GSH transport at the blood-brain barrier and molecular characterisation of novel brain GSH transporters. In:Glutathione in the Nervous System Shaw CA (Ed), Taylor & Francis, Washington, DC, USA 45-62 (1998).
24. Kannan R, Mittur A, Bao Y, Tsuruo T, Kaplowitz N. GSH transport in immortalized mouse brain endothelial cells: evidence for apical localization of a sodium-dependent GSH transporter. J. Neurochem. 73, 390-399 (1999). (Pubitemid 29289148)
25. Zlokovic BV, Mackic JB, McComb JG, Weiss MH, Kaplovitz N, Kannan R. Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem. Biophys. Res. Comm. 201 (1) 402-408 (1994) (Pubitemid 24213740)
26. Rip J, Appeldoorn CC, Manca FM, Dorland R, van Kregten JM, Gaillard PJ. Receptor-mediated delivery of drugs across the blood-brain barrier. Presented at: Pharmacology and Toxicology of the Blood- Brain Barrier: State of the Art, Needs for Future Research and Expected Benefits for the EU. Brussels, Belgium, 11-12 February 2010.
27. van Tellingen O, Brandsma D, Appeldoorn CC et al. GSH-conjugation improves efficacy of Doxil against intracranial xenografts. Presented at: The Annual Meeting of the AACR. Washington DC, USA, 17-21 April 2010.
28. Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25 (16), 2295-2305 (2007). (Pubitemid 46954658)
29. Pardridge WM. shRNA and siRNA delivery to the brain. Adv. Drug Delivery Rev. 59, 141-152 (2007). (Pubitemid 46773051)
30. Pardridge WM. Biopharmaceutical drug targeting to the brain. J. Drug Target. 18 (3), 157-167 (2010).
31. Zhang Y, Pardridge WM. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res. 1111, 227-229 (2006). (Pubitemid 44339581)
32. Wu D, Pardridge WM. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J. Pharmacol. Exp. Ther. 279, 77-83 (1996). (Pubitemid 27166896)
33. Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc. Natl Acad. Sci. USA 96, 254-259, (1999). (Pubitemid 29036086)
34. Song BW, Vinters HV, Wu D, Pardridge WM. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J. Pharmacol. Exp. Ther. 301, 605-610 (2002). (Pubitemid 34429974)
35. Kurihara A, Pardridge WM. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res. 59, 6159-6163 (1999). (Pubitemid 30035637)
36. Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Ab peptide radiopharmaceutical. J. Cereb. Flow Metab. 22, 223-231 (2002). (Pubitemid 34135653)
37. Zhang Y, Pardridge WM. Near complete rescue of experimental Parkinson's disease with intravenous nonviral GDNF gene therapy. Pharma. Res. 26 (5), 1059-1063 (2009).
38. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrinreceptor- antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharma. Biopharm. 71, 251-256 (2009).
39. Coloma MJ, Lee HJ, Kurihara A et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 17, 266-274 (2000). (Pubitemid 30225129)
40. Boado RJ, Zhang Y, Wang Y, Pardridge WM. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotech. Bioeng. 100, 387-396 (2008). (Pubitemid 351758180)
41. Pardridge WM, Boado RJ. Pharmacokinetics and safety in Rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeting blood-brain barrier delivery. Pharma. Res. 26 (10), 2227-2236 (2009).
42. Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J. Drug Target. DOI:10.3109/10611861003734001 (2010) (Epub ahead of print).
43. Zensi A, Begley D, Pontikis C et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Contr. Rel. 137, 78-86 (2009).
44. Hertz J, Strickland DK. LRP: a multifunctional scavenger and signalling receptor. J. Clin. Invest. 108, 779-784 (2001). (Pubitemid 32880284)
45. Kounnas MZ, Moir RD, Rebeck GW et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted b-amyloid precursor protein and mediates its degradation. Cell 82, 331-340 (1995).
46. Yoon I-S, Chen E, Busse T et al. Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway. FASEB J. 21, 2742-2752 (2007). (Pubitemid 47372742)
47. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11, 575-580 (1993). (Pubitemid 23321768)
48. Bu G, Maksymovitch EA, Nerbonne JM, Schwartz AL. Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J. Biol. Chem. 269, 18521-18528 (1994). (Pubitemid 24224088)
49. Wolf BB, Lopes MBS, VandenBerg SR, Gonias SL. Characterization and immunohistochemical localization of a2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am. J. Pathol. 141, 37-42 (1992).
50. Moestrup SK, Gliemann J, Pallesen G. Distribution of the a2-macroglobulin receptor/low density lipoprotein receptorrelated protein in human tissues. Cell Tissue Res. 269, 375-342 (1992).
51. Yamamoto M, Ikeda K, Ohshima K, Tsugu H, Kimura H, Tomonaga M. Increased expression of low density lipoprotein receptor-related protein/a2-macroglobulin receptor in human malignant astrocytomas. Cancer Res. 57, 2799-2805 (1997). (Pubitemid 27283795)
52. Li Y, Marzolo MP, van Kerkhof P, Strous GJ, Bu G. The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low-density lipoprotein receptor-related protein. J. Biol. Chem. 275 (22), 17187-17194 (2000). (Pubitemid 30398967)
53. Benchenane K, Berezowski V, Ali C et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 111, 2241-2249 (2005). (Pubitemid 40632441)
54. Donoso M, Cancino J, Lee J et al. Polarized traffic of LRP1 involves AP1B and SNX17 operating on Y-dependent sorting motifs in different pathways. Mol. Biol. Cell. 20, 481-497 (2009).
55. Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-b peptide in a blood-brain barrier in vitro model. Neurobiol. Dis. 30, 94-102 (2008).
56. Hussain MM, Strickland DK, Bakillah A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 19, 141-172 (1999). (Pubitemid 29380600)
57. Weber C, Kreuter J, Langer K. Desolvation process and surface characteristics of HSA-nanoparticles. Int. J. Pharm. 196 (2), 197-200 (2000). (Pubitemid 30105742)
58. Michaelis K, Hoffmann MM, Dreis S et al. Covalent linkage of Apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317 (3), 1246-1253 (2006). (Pubitemid 43764130)
59. Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles anables drug transport into the brain. J. Contr. Rel. 118, 54-58 (2007). (Pubitemid 46283106)
60. Kreuter J. Application of nanoparticles for the delivery of drugs to the brain. In:Drug Transport(ers) and the Diseased Brain International Congress Series, Esteve Foundation Symposium XI , S'Agaró (Girona), Spain, de Boer AG (Ed), Elsevier 1277, 85-94 (2005). (Pubitemid 43693337)
61. Kreuter J, Ramge P, Petrov V et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharma. Res. 20, 409-416 (2003). (Pubitemid 36288370)
62. Steiniger SCJ, Kreuter J, Khalansky AS et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109, 759-767 (2004). (Pubitemid 38405625)
63. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2, 108-119 (2005).
64. Kreuter J, Shamenkov D, Petrov V et al. Apolipoprotein-mediated transport of nanoparticles-bound drugs across the blood-brain barrier. J. Drug Target. 10, 317-325 (2002). (Pubitemid 34746313)
65. Kurakhmaeva KB, Djindjikhashvili IA, Petro VE et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Target. 17(8), 564-574 (2009).
66. Gelperina S, Maksimenko O, Khalansky A et al. Drug delivery to the brain using surfactant-coated poly(lactide-coglycolide) nanoparticles: influence of the formulation parameters. Eur. J. Pharma. Biopharma. 74, 157-163 (2010).
67. Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl Acad. Sci. USA 104, 7594-7599 (2007). (Pubitemid 47185951)
68. Huang R, Ke W, Liu Y, Jiang C, Pei Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 29, 238-246 (2008). (Pubitemid 350016299)
69. Jefferies WA, Food M, Gabathuler R, Rothenberger S, Yamada T, McGeer PL. Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res. 712, 122-126 (1996). (Pubitemid 26099932)
70. Food M, Rothenberger S, Gabathuler R, Haidl ID, Reid G, Jefferies WA. Transport and expression in human melanomas of a transferrin like glycosylphosphatidylinositolanchored proteins. J. Biol. Chem. 269, 3034-3040 (1994). (Pubitemid 24235812)
71. Demeule M, Poirier J, Jodoin J et al. High transcytosis of melanotransferrin (p97) across the blood-brain barrier. J. Neurochem. 83, 924-933 (2002). (Pubitemid 35316043)
72. Gabathuler R, Arthur G, Kennard ML et al. Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier. In:Drug Transport(ers) and the Diseased Brain , Int Congress Series, Esteve Foundation Symposium XI , S'Agaró (Girona), Spain, de Boer AG (Ed), Elsevier 1277, 171-184 (2005). (Pubitemid 43693327)
73. Karkan D, Pfeifer C, Vitalis TZ et al. A unique carrier for delivery of therapeutical compounds beyond the blood-brain barrier. PLoS One 3, e2469 (2008).
74. Pan W, Kastin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci. 117, 5071-5078 (2004). (Pubitemid 39517522)
75. Migliorini MM, Behre EH, Brew S, Ingham KC, Strickland DK. Allosteric modulation of ligand binding to low density lipoprotein receptor-related protein by the receptor-associated protein requires critical lysine residues within the carboxy-terminal domain. J. Biol. Chem. 278, 17986-17992 (2003). (Pubitemid 36799407)
76. Prince WS, McCormick LM, Wendt DJ et al. Lipoprotein receptor binding, cellular uptake and lysosomal delivery of fusions between the receptor-associated protein (RAP) and a-l-iduronidase or acid a-glucosidase. J. Biol. Chem. 279, 35037-35046 (2004). (Pubitemid 39318140)
77. Liu Y, Jones M, Hingten CM et al. Uptake of HIV-1 Tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nature Med. 6(12), 1380-1387 (2000). (Pubitemid 32001023)
78. Demeule M, Regina A, Che C et al. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324, 1064-1072 (2008). (Pubitemid 351397849)
79. Demeule M, Currie J-C, Bertrand Y et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J. Neurochem. 106, 1534-1544 (2008).
80. Che C, Yang G, Thiot C et al. New angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J. Med. Chem. 53, 2814-2824 (2010).
81. Bertrand Y, Currie JC, Demeule M et al. Transport characteristics of a novel peptide platform for CNS therapeutics. J. Cell. Mol. Med. DOI:10.1111/j.1582-4934.2009.00930.x (2009) (Epub ahead of print).
82. Bertrand Y, Currie JC, Demeule M et al. Uptake of the new paclitaxel-derivative (ANG1005) by the low-density lipoprotein receptor-related protein1 (LRP1) is related to the aggressive phenotype of glioblastoma cells. Presented at: The Annual Meeting of the AACR. Washington DC, USA, 17-21 April 2010.
83. Smith QR. A review of blood-brain barrier transport techniques. Methods Mol. Med. 89, 193-208 (2003).
84. Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion techniques to study cerebrovascular transport in the rat. Am. J. Physiol. 247, 484-493 (1984).
85. Thomas FC, Taskar K, Rudraraju V et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharma. Res. 26(11) 2486-2494 (2009).
86. Demeule M, Régina A, Yang G et al. New angiochem-modified doxorubicin with increased brain penetration and efficacy against brain tumors. Presented at: The Annual Meeting of the AACR, Washington DC, USA, 17-21 April 2010.
87. Regina A, Demeule M, Che C et al. Anti-tumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155, 185-197 (2008).
88. Bichat F, Demeule M, Lawrence B et al. Enhanced drug delivery to brain tumors with a new paclitaxel-peptide conjugate. Eur. J. Cancer Suppl. 6, 45, 139 (2008).
89. Gabathuler R. An engineered peptide compound platform technology incorporating Angiopep for crossing the BBB. In:Drug Delivery to the CNS Neuromethods 45 Jain KK (Ed). Humana Press, NY, USA, 249-260 (2010).
90. Drappatz J, Brenner A, Rosenfeld S et al. ANG1005: development of a new engineered peptide compound (EPiC) for the treatment of malignant glioma. Presented at: The Annual Neuroscience Conference 2009. Chicago, IL, USA, 17-21 October 2009.
91. Kurzrock R, Gabrail N, Moulder S et al. ANG1005: a promising new engineered peptide compound (EPiC) for patients with advanced solid tumors and brain metastases. Presented at: The Annual Neuroscience Conference 2009. Chicago, IL, USA, 17-21 October 2009.
92. Biowire industry updates: Angiochem presents complete phase 1/2 clinical data for ANG1005: further benefits of targeting LRP-1 pathway in cancer. Genetic Engineering & Biotechnology News, 7 June (2010)
93. Drappatz J, Brenner AJ, Rosenfeld S et al. ANG1005: results of a Phase I study in patients with recurrent malignant glioma. J. Clin. Oncol. 28, 7s (Suppl. 2009) (2010).
94. Sarantopoulos J, Gabrail NY, Moulder SL et al. ANG1005: results of a Phase I study in patients with advanced solid tumors and brain metastases. J. Clin. Oncol. 28, 7s (Suppl. 2556) (2010).
95. Ke W, Shao K, Huang R et al. Gene delivery targeted to the brain using an angiopepconjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30 (36), 6976-6985 (2009).
96. Tanha J, Dubuc G, Hirama T, Narang SA, MacKenzie CR. Selection by phage display of llama conventional VH fragments with heavy chain antibody VHH properties. J. Immunol. Meth. 263, 97-109 (2002). (Pubitemid 34493813)
97. Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 16, 240-242 (2002).
98. Tanha J, Muruganandam A, Stanimirovic D. Phage display technology for identifying specific antigens on brain endothelial cells. Meth. Mol. Med. 89, 435-449 (2003).
99. Abulrob A, Sprong H, Bergen en Henegouwen PV, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem. 95, 1201-1214 (2005). (Pubitemid 41713502)
100. Paulusma CC, Folmer DE, Ho-Mok KS et al. ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology 47, 268-278 (2008). (Pubitemid 351171064)
101. Drin G, Rousselle C, Scherrmann J-M, Rees AR, Temsamari J. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci 4(4), 1-7 (2002).
102. Drin G, Cottin S, Blanc E, Rees AR, Temsamari J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 278 (33), 31192-31201 (2003). (Pubitemid 36994635)
103. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. J. Pharmacol. Exp. Ther. 57, 679-686 (2000). (Pubitemid 30183706)
104. Rousselle C, Clair P, Smirnova M et al. Improved brain uptake and pharmacological activity of dalargin using a peptide-vectormediated strategy. J. Pharmacol. Exp. Ther. 306, 371-376 (2003). (Pubitemid 36734394)
105. Temsamani J, Bonnafous C, Rousselle C et al. Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy. J. Pharmacol. Exp. Ther. 313, 712-719 (2005). (Pubitemid 40604172)
106. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl Acad. Sci. USA 97, 13003-13008 (2000).
107. Temsamani J, Rousselle C, Rees AR, Scherrmann J-M. Vector-mediated drug delivery to the brain. Exp. Opin. Biol. Ther. 1, 773-782 (2001). (Pubitemid 33769737)
108. Pham W, Zhao B-Q, Lo EH, Medarova Z, Rosen B, Moore A. Crossing the blood-brain barrier: a potential application of myristoylated polyarginine for in vivo imaging. Neuroimage 28, 287-292 (2005). (Pubitemid 41393908)
109. Kumar P, Wu H, McBride JL et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 33-40 (2007).
110. Cui D, Xu Q, Gu S, Shi J, Che X. PAMAMdrug complex for delivering anticancer drug across the blood-brain barrier in vitro and in vivo. Afr. J. Pharm. Pharmacol. 3, 227-233 (2009).
111. Liu Y, Huang R, Han L et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30, 4195-4202 (2009).
112. Santra S, Yang H, Stanley JT et al. Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem. Commun. 25, 3144-3146 (2005). (Pubitemid 41002376)
113. Liu L, Guo K, Lu J et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 29, 1509-1517 (2008).
114. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 29, 4429-4438 (2008).
115. Rao KS, Labhasetwar V. Trans-activating transcriptional activator (TAT) peptidemediated brain drug delivery. J. Biomed. Nanotech. 2, 173-185 (2006).
116. Dennisson SR, Baker RD, Nicholl ID, Phoenix DA. Interactions of cell penetrating peptide TAT with model membranes: a biophysical study. Biochem. Biophys. Res. Commun. 363, 178-182 (2007). (Pubitemid 47430110)